
Natsumi Inoue

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9661333/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hirayama disease. Joint Bone Spine, 2022, , 105354.	1.6	0
2	Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch–SchA¶nlein purpura nephritis. Pediatric Research, 2021, 89, 667-672.	2.3	7
3	Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology, 2021, 60, 231-238.	1.9	18
4	Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis. Rheumatology, 2021, 60, 2421-2426.	1.9	21
5	A Bladder Mass in a Patient with Henoch-Schönlein Purpura. Journal of Pediatrics, 2021, 231, 289-290.	1.8	1
6	Successful treatment of spondyloenchondrodysplasia with baricitinib. Rheumatology, 2021, 60, e44-e46.	1.9	2
7	Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic Escherichia coli induced hemolytic uremic syndrome. Renal Failure, 2021, 43, 382-387.	2.1	2
8	Concurrent Treatment With Rituximab and Plasma Exchange for Rapidly Progressive Interstitial Lung Disease Complicating Anti-MDA5 Antibody–Positive Juvenile Dermatomyositis. Journal of Clinical Rheumatology, 2021, 27, S798-S799.	0.9	5
9	Rapid molecular diagnosis of Parechovirus infection using the reverse transcription loop-mediated isothermal amplification technique. PLoS ONE, 2021, 16, e0260348.	2.5	3
10	Periorbital Edema as the Initial Sign of Juvenile Dermatomyositis. Journal of Clinical Rheumatology, 2020, 26, e61-e61.	0.9	3
11	Clinical usefulness of longitudinal IL-6 monitoring in a patient with Takayasu aortitis receiving tocilizumab. Rheumatology, 2020, 59, 252-254.	1.9	5
12	Chronic recurrent multifocal osteomyelitis with myositis: A case report and review of the literature. Pediatrics International, 2020, 62, 644-645.	0.5	1
13	Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy. Journal of Immunology Research, 2020, 2020, 1-10.	2.2	5
14	Successful treatment of tumor necrosis factor inhibitorâ€resistant cutaneous polyarteritis nodosa with tocilizumab. Pediatrics International, 2020, 62, 753-755.	0.5	5
15	Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy. Pediatric Research, 2020, 88, 934-939.	2.3	10
16	Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Clinical Immunology, 2019, 208, 108252.	3.2	26
17	Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus. Clinical Immunology, 2019, 208, 108255.	3.2	11
18	Cytokine profile of macrophage activation syndrome associated with Kawasaki disease. Cytokine, 2019, 119, 52-56.	3.2	33

NATSUMI INOUE

#	Article	IF	CITATIONS
19	Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis. Journal of Immunology Research, 2019, 2019, 1-6.	2.2	13
20	Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome. Cytokine, 2019, 119, 182-187.	3.2	31
21	FRI0535â€COMPARISON OF SERUM BIOMARKERS FOR THE DIAGNOSIS OF MACROPHAGE ACTIVATION SYNDROME COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL SIGNIFICANCE OF SERUM NEOPTERIN LEVELS. , 2019, , .		0
22	AB1044â€CYTOKINE PROFILE OF MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH KAWASAKI DISE , 2019, , .	ASE.	0
23	OP0328â€COMPARISON OF SERUM CYTOKINE PROFILE IN MACROPHAGE ACTIVATION SYNDROME AMONG DIFFERENT BACKGROUND RHEUMATIC DISEASES IN CHILDREN:. , 2019, , .		1
24	Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli. Clinical and Experimental Nephrology, 2019, 23, 544-550.	1.6	4
25	Clinical significance of serum soluble TNF receptor II level and soluble TNF receptor II/I ratio as indicators of coronary artery lesion development in Kawasaki disease. Cytokine, 2018, 108, 168-172.	3.2	14
26	Successful treatment of rituximab―and steroidâ€resistant nephrotic syndrome with leukocytapheresis. Journal of Clinical Apheresis, 2018, 33, 409-411.	1.3	2
27	Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine, 2018, 110, 459-465.	3.2	34
28	Angiopoietin-1 and -2 as markers for disease severity in hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli. Clinical and Experimental Nephrology, 2017, 21, 76-82.	1.6	7
29	Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series. Modern Rheumatology, 2017, 27, 833-837.	1.8	13
30	Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Clinical and Experimental Nephrology, 2017, 21, 1083-1087.	1.6	5
31	<scp>FDG</scp> â€ <scp>PET</scp> in macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Pediatrics International, 2017, 59, 509-511.	0.5	0
32	Thrombocytosisâ€related glomerulopathy in a patient with hyposplenia. Pediatrics International, 2017, 59, 842-843.	0.5	1
33	Refractory cutaneous polyarteritis nodosa: Successful treatment with etanercept. Pediatrics International, 2017, 59, 751-752.	0.5	7
34	Interleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Modern Rheumatology, 2017, 27, 609-613.	1.8	4
35	Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. Clinical Immunology, 2016, 169, 8-13.	3.2	106
36	Successful treatment of exertional heat stroke using continuous plasma diafiltration. Journal of Clinical Apheresis, 2016, 31, 490-492.	1.3	7

NATSUMI INOUE

#	Article	IF	CITATIONS
37	Leopard skin appearance of cutaneous polyarteritis nodosa on ^{18F} fluorodeoxyglucose positron emission tomography. Rheumatology, 2016, 55, 1090-1090.	1.9	11
38	Immunostaining of Sulfatide-Storing Macrophages in Gallbladder of a Patient With Metachromatic Leukodystrophy. Pediatric Neurology, 2016, 64, e3-e4.	2.1	1
39	Clinical Usefulness of 18F-fluorodeoxyglucose Positron Emission Tomography for Enthesitis-related Arthritis Diagnosis. Journal of Rheumatology, 2016, 43, 1434-1435.	2.0	1
40	Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease. Modern Rheumatology, 2016, 26, 929-932.	1.8	36
41	Disruption of vascular endothelial homeostasis in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The dynamic roles of angiopoietin-1 and -2. Cytokine, 2016, 80, 1-6.	3.2	3
42	The critical role of lipopolysaccharide in the upregulation of aquaporin 4 in glial cells treated with Shiga toxin. Journal of Biomedical Science, 2015, 22, 78.	7.0	13
43	Iodineâ€induced nonâ€autoimmune hypothyroidism in a patient with steroidâ€resistant nephrotic syndrome. Pediatrics International, 2015, 57, 1055-1056.	0.5	1
44	Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome. Neurochemistry International, 2015, 85-86, 24-30.	3.8	11
45	Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clinical Immunology, 2015, 160, 277-281.	3.2	135
46	Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology, 2014, 53, 2120-2122.	1.9	9
47	Successful multitarget therapy using mizoribine and tacrolimus for refractory Takayasu arteritis. Rheumatology, 2014, 53, 1530-1532.	1.9	5
48	Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine, 2014, 66, 1-6.	3.2	18